Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
08/05/2024 | 13:00 | Business Wire | Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
25/04/2024 | 13:00 | Business Wire | Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
18/04/2024 | 13:00 | Business Wire | Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
28/03/2024 | 12:00 | Business Wire | Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
07/03/2024 | 22:54 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
07/03/2024 | 22:48 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
07/03/2024 | 22:40 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
07/03/2024 | 22:06 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
06/02/2024 | 13:00 | Business Wire | Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
29/01/2024 | 23:25 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
04/01/2024 | 13:00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
04/01/2024 | 13:00 | Business Wire | Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
19/12/2023 | 13:00 | Business Wire | Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
18/12/2023 | 22:01 | Business Wire | Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
27/11/2023 | 22:07 | Business Wire | Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
03/11/2023 | 21:08 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
01/11/2023 | 12:05 | Business Wire | Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
27/09/2023 | 11:45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX) | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
11/09/2023 | 23:42 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
11/08/2023 | 11:45 | PR Newswire (US) | ALDX SHAREHOLDER ALERT: Jakubowitz Law Reminds Aldeyra Shareholders of a Lead Plaintiff Deadline of September 29, 2023 | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
06/07/2023 | 13:00 | Business Wire | Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
29/06/2023 | 22:24 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
29/06/2023 | 13:02 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
29/06/2023 | 13:00 | Business Wire | Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
28/06/2023 | 22:01 | Business Wire | Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
27/06/2023 | 13:00 | Business Wire | Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
26/06/2023 | 22:01 | Business Wire | Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
23/06/2023 | 13:00 | Business Wire | Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
21/06/2023 | 15:34 | Business Wire | Aldeyra Therapeutics Provides Regulatory Update on ADX-2191 | NASDAQ:ALDX | Aldeyra Therapeutics Inc |
15/06/2023 | 13:00 | Business Wire | Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic Conjunctivitis | NASDAQ:ALDX | Aldeyra Therapeutics Inc |